| Literature DB >> 33675683 |
Fang Chen1, Netanel Tzarum2, Xiaohe Lin1, Erick Giang1, Rodrigo Velázquez-Moctezuma3, Elias H Augestad3, Kenna Nagy1, Linling He1, Mayda Hernandez4, Mallorie E Fouch4, Ariadna Grinyó4, Deborah Chavez5, Benjamin J Doranz4, Jannick Prentoe3, Robyn L Stanfield2, Robert Lanford5, Jens Bukh3, Ian A Wilson6, Jiang Zhu7, Mansun Law8.
Abstract
Human IGHV1-69-encoded broadly neutralizing antibodies (bnAbs) that target the hepatitis C virus (HCV) envelope glycoprotein (Env) E2 are important for protection against HCV infection. An IGHV1-69 ortholog gene, VH1.36, is preferentially used for bnAbs isolated from HCV Env-immunized rhesus macaques (RMs). Here, we studied the genetic, structural, and functional properties of VH1.36-encoded bnAbs generated by vaccination, in comparison to IGHV1-69-encoded bnAbs from HCV patients. Global B cell repertoire analysis confirmed the expansion of VH1.36-derived B cells in immunized animals. Most E2-specific, VH1.36-encoded antibodies cross-neutralized HCV. Crystal structures of two RM bnAbs with E2 revealed that the RM bnAbs engaged conserved E2 epitopes using similar molecular features as human bnAbs but with a different binding mode. Longitudinal analyses of the RM antibody repertoire responses during immunization indicated rapid lineage development of VH1.36-encoded bnAbs with limited somatic hypermutation. Our findings suggest functional convergence of a germline-encoded bnAb response to HCV Env with implications for vaccination in humans.Entities:
Keywords: E1E2; E2; Hepatitis C virus; IGHV1-69; VH1-69; VH1.36; antibody germline; broadly neutralizing antibody; immunization; vaccination
Mesh:
Substances:
Year: 2021 PMID: 33675683 PMCID: PMC8046733 DOI: 10.1016/j.immuni.2021.02.013
Source DB: PubMed Journal: Immunity ISSN: 1074-7613 Impact factor: 31.745